Search

Your search keyword '"Pogany, K."' showing total 49 results

Search Constraints

Start Over You searched for: Author "Pogany, K." Remove constraint Author: "Pogany, K."
49 results on '"Pogany, K."'

Search Results

1. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

2. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study

3. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

4. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

5. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

7. Management of drug interactions with direct‐acting antivirals in Dutch HIV/hepatitis C virus‐coinfected patients: adequate but not perfect

8. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

9. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

10. A highly virulent variant of HIV-1 circulating in the Netherlands

12. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

13. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

15. Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM

16. Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV

20. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

21. Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort

22. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

23. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

24. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

25. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

27. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

28. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

29. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

30. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

31. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

32. Has the Rate of CD4 Cell Count Decline before Initiation of Antiretroviral Therapy Changed over the Course of the Dutch HIV Epidemic among MSM?

34. Effects of active treatment discontinuation in patients with a CD4(+) T-cell nadir greater than 350 cells/mm(3)

35. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

37. Immunological analysis of treatment interruption after early highly active antiretroviral therapy

42. Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response

43. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

46. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

47. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

48. Immunological analysis of treatment interruption after early highly active antiretroviral therapy.

49. Ultrasonographic appearance of the conceptus, fetal heart rate and profiles of pregnancy-associated glycoproteins (PAG) and prostaglandin F2alpha-metabolite (PGF2alpha-metabolite) after induction of fetal death with aglepristone during early gestation in cattle.

Catalog

Books, media, physical & digital resources